A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer

T J Hamblin, S Sadullah, P Williamson, J Stevenson, R Oskam, P Palmer, C R Franks

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)

Abstract

Sixteen patients with metastatic colorectal cancer have been treated with a regimen involving an 120 h continuous infusion of rIL-2, 18 x 10(6) iu m-2 day followed by three injections of 5FU 600 mg m-2 at weekly intervals. Entry criteria included no previous chemotherapy, ambulatory performance status, and a measurable lesion. In most cases side effects were easily manageable and only one patient required transfer to an intensive care unit with the capillary leak syndrome. In three patients persistent hypotension was found to be unrelated to treatment with rIL-2, being caused respectively by a line infection, pulmonary embolus, and bowel perforation. This last proved a fatal complication. Five patients (33%; [95% confidence limits, 11.8%-61.6%]) achieved a partial response, and two non-responders later achieved a partial response when treated with weekly 5FU. This regimen is currently being evaluated in a phase-III randomised controlled trial.

Original languageEnglish
Pages (from-to)1186-9
Number of pages4
JournalBritish Journal of Cancer
Volume68
Issue number6
Publication statusPublished - Dec 1993

Keywords

  • Abdominal Neoplasms/drug therapy
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols/adverse effects
  • Capillary Permeability
  • Colorectal Neoplasms/drug therapy
  • Drug Administration Schedule
  • Female
  • Fluorouracil/administration & dosage
  • Humans
  • Hypotension/chemically induced
  • Infusions, Intravenous
  • Injections, Intravenous
  • Interleukin-2/administration & dosage
  • Intestinal Perforation/complications
  • Liver Neoplasms/drug therapy
  • Lung Neoplasms/drug therapy
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Pulmonary Embolism/complications
  • Recombinant Proteins/administration & dosage
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this